Re–Vana Therapeutics Ltd

Eyconis

The company develops long-acting ophthalmic medicines for patients with retinal diseases such as wet age-related macular degeneration.

VisusNano

This company develops drug-eluting intraocular lens implants for patients undergoing cataract surgery to eliminate the need for post-operative eye drops.

Perfuse Therapeutics

The company develops sustained-release intravitreal therapies to treat ischemia-driven ocular diseases for patients with conditions like glaucoma and diabetic retinopathy.

Biophta

This company develops self-administered ocular inserts providing seven-day continuous drug release for patients with glaucoma and macular oedema.

EyeBio

This biotechnology company develops ocular therapies to treat retinal diseases such as diabetic macular edema and age-related macular degeneration for patients with vision loss.

Eyexora

This company develops therapeutics and medical devices for ophthalmic diseases to treat patients with vision-threatening conditions.

Graybug Vision

The company develops sustained-release injectable medicines for patients with retinal diseases and glaucoma to reduce the frequency of ocular treatments.

Eyebiotech Limited

This clinical-stage biotechnology company develops therapies for retinal diseases, such as diabetic macular edema and age-related macular degeneration, to protect and restore patient vision.